Beroni Group Limited

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) today announced its further progress on the development of a medical solution using nanobody technology for the COVID-19 coronavirus in collaboration with Tianjin University in China.

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it is collaborating with Forsitech Inc. and Standard Capital Co., Ltd to supply its SARS-CoV-2 total antibody detection kit for clinical testing in the Japanese market.

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it has appointed Dr. Richard Buchta as an independent non-executive director of the Company

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that, the Company has completed the issue of 2,390,000 fully paid ordinary shares to the Directors, employees and scientists.

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has raised US$2.97 million via the issue of convertible notes to professional and sophisticated investors in Japan.